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Psoriasis is a complex immune-mediated inflammatory skin disease characterized by 
T-cell-driven epidermal hyperplasia. It occurs on a strong genetic predisposition. The 
human leukocyte antigen (HLA)-class I allele HLA-C*06:02 on psoriasis susceptibility 
locus 1 (PSORS1 on 6p21.3) is the main psoriasis risk gene. Other HLA-class I alleles 
encoding HLA molecules presenting overlapping peptide repertoires show associations 
with psoriasis as well. Outside the major histocompatibility complex region, genome-
wide association studies identified more than 60 psoriasis-associated common gene 
variants exerting only modest individual effects. They mainly refer to innate immune 
activation and the interleukin-23/Th/c17 pathway. Given their strong risk association, 
explaining the role of the HLA-risk alleles is essential for elucidating psoriasis pathogen-
esis. Psoriasis lesions develop upon epidermal infiltration, activation, and expansion of 
CD8+ T cells. The unbiased analysis of a paradigmatic Vα3S1/Vβ13S1-T-cell receptor 
from a pathogenic epidermal CD8+ T-cell clone of an HLA-C*06:02+ psoriasis patient 
had revealed that HLA-C*06:02 directs an autoimmune response against melanocytes 
through autoantigen presentation, and it identified a peptide form ADAMTS-like protein 
5 as an HLA-C*06:02-presented melanocyte autoantigen. These data demonstrate 
that psoriasis is an autoimmune disease, where the predisposing HLA-class I alleles 
promote organ-specific inflammation through facilitating a T-cell response against a par-
ticular skin-specific cell population. This review discusses the role of HLA-class I alleles 
in the pathogenic psoriatic T-cell immune response. It concludes that as a principle 
of T-cell driven HLA-associated inflammatory diseases proinflammatory traits promote 
autoimmunity in the context of certain HLA molecules that present particular autoantigens.
Keywords: psoriasis, pathogenesis, autoreactive T  cells, human leukocyte antigen association, HLA-C*06:02, 
T-cell receptor, autoimmunity, autoantigens
inTRODUCTiOn
Psoriasis is a complex T-cell mediated skin disease. Skin lesions are characterized by sharply demar- 
cated heavily scaling inflammatory plaques which result from T-cell driven epidermal hyperplasia. 
T cells infiltrating psoriasis skin lesions display a T-helper/cytotoxic cell (Th/c) 17 phenotype pro-
ducing the Th/c17 signature cytokines interleukin (IL)-17A, IL-22, and IFN-γ (1, 2). They promote 
keratinocyte proliferation, accumulation of neutrophilic granulocytes, and the production of antimi-
crobial peptides and other inflammatory cytokines and chemokines. Activation and differentiation 
Abbreviations: TCR, T-cell receptor; GWAS, genome-wide association study; HLA, human leukocyte antigen; MHC, major 
histocompatibility complex; ADAMTSL5, ADAMTS-like protein 5.
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of the lesional psoriatic Th/c17 response is maintained by IL-23 
that is produced by local dendritic cells and keratinocytes. By 
today, blocking IL-17A or IL-23 represents the most efficient 
treatment modality (3).
Psoriasis is multifactorial and involves the interaction of 
individual genotypes with environmental, infectious, and lifestyle 
factors. The human leukocyte antigen (HLA)-class I allele HLA-
C*06:02 is the main psoriasis risk gene (4–6). Functional cluster-
ing of common variants associated with psoriasis highlighted 
the roles of interferon signaling and the NF-κB cascade and of 
regulatory elements related to CD4+ and CD8+ T cell maturation, 
development, and activation including the IL-23 pathway and 
Th/c17 differentiation (7). Thus, understanding psoriasis patho-
genesis has to explain the role of HLA-C*06:02 within the com-
plex genetic background predisposing to psoriasis. Therefore, 
this review will focus on the functional implications of the main 
HLA psoriasis risk gene, HLA-C*06:02.
HLA-CLASS i ASSOCiATiOn OF 
PSORiASiS: THe MAin GeneTiC RiSK
The most significant association signal observed in psoriasis 
genome-wide association studies that satisfied the genome-wide 
significance threshold of P < 5.0 × 10−8 (8) was observed within 
the major histocompatibility complex (MHC) region (7, 9–13). 
The highly polymorphic nature and density of genes and the 
extensive linkage disequilibrium that exists within the MHC, 
however, had initially hampered the identification of the causal 
gene that confers psoriasis susceptibility in the HLA region. 
Sequence-based methods in large samples finally proved HLA-
C*06:02 as the main psoriasis risk gene (4, 6). HLA-C*06:02 
defines early onset, severity and familial clustering of psoriasis 
(14–16). Unlike HLA-class II-associated autoimmune diseases 
psoriasis shows no evidence of interactions between different 
HLA alleles. HLA-C*06:02 contributes a non-additive risk effect 
and represents a true HLA-class I risk gene (17).
Interpreting HLA associations has to consider that the fre-
quency of alleles can differ between populations. The prevalence 
and incidence of psoriasis shows ethnic and geographic variations. 
A relatively high prevalence of psoriasis in European countries 
and in the USA (0.5–6.5%) contrasts with a low prevalence in East 
Asian countries (0.2–0.3%) (18, 19). Given the strong risk effect of 
HLA-C*06:02, the ethnic allele frequency spectra of HLA-C*06:02 
may at least partially explain the heterogeneity of psoriasis in 
different ethnic populations. This highlights the need to use 
population-specific reference panels made by deep sequencing to 
impute MHC alleles and amino acids (8). The strong psori asis risk 
of HLA-C*06:02 allele has been validated in worldwide popula-
tions including Europeans (17, 20), East (6, 21), and South Asians 
(22), with odds ratios of as high as 3.0–10.0. HLA fine-mapping 
analysis using the HLA imputation method successfully identi-
fied multiple other less obviously associated HLA-class I and 
class II variants that confer psoriasis risk independently from 
HLA-C*06:02 (20). Aside from HLA-C*06:02 psoriasis associated 
with HLA-C*12:03, HLA-C*07:01, HLA-C*07:02, HLA-C*07:04, 
HLA-B*27, and HLA-B*57. Further associations were seen with 
HLA-B amino acid positions 9, 67, and 116, HLA-A amino acid 
95, and HLA-DQα1 amino acid position 53 which are all localized 
within the HLA antigen binding region (6, 20, 21, 23). Although 
HLA-C*06:02 and the AA position 67 of HLA-B are shared bet-
ween Caucasian and Chinese populations, other independent 
HLA-risk variants differ between the two populations. HLA-
A*02:07, which corresponds to the cysteine residue at HLA-A 
position 99, shows a strong association in Chinese but is very 
rare or absent in Europeans, whereas HLA-B*07 shows a strong 
association in Caucasians while it is very rare in Chinese. The 
other HLA variants are common in both Caucasian and Chinese, 
but show population-specific associations, HLA-A*02:01 for Cau-
casian and the AA positions 114 and 144 of HLA-A for Chinese. 
These population-specific effects contribute significantly to the 
ethnic diversity of psoriasis prevalence (12).
The Japanese population has unique characteristics. Psoriasis 
prevalence in Japan is one of the lowest compared with worldwide 
populations (0.1–0.3%) (24–27), and HLA-C*06:02 is almost 
absent within the Japanese population (<0.5%) (21). Due to low 
allele frequency in the Japanese population, the impact of HLA-
C*06:02 on psoriasis susceptibility in Japanese psoriasis patients 
was less apparent compared with that seen in other populations 
(2.3% in psoriasis cases and 0.4% in controls). Still, a Japanese-
specific reference panel showed increased odds ratios for 
HLA-C*06:02, HLA-C*12:02, and HLA-C*07:04 in the Japanese 
psoriasis population (21).
Interestingly, several of the psoriasis-associated HLA-class I 
alleles are also significantly increased in Crohn’s disease (HLA-
C*06:02, HLA-C*12:02) and ulcerative colitis (HLA-C*12:02, 
HLA-C*07:02) (28). HLA-B*27 predisposes for ankylosing spon-
dylitis, inflammatory bowel disease, and psoriasis arthritis, 
creating an overlapping HLA-class I risk pattern although no 
autoantigens have been identified in these diseases.
FUnCTiOnAL ASPeCTS OF HLA-CLASS i 
ALLeLeS in PSORiASiS
Genetic variation in HLA genes within the MHC locus is 
associated with many immune-mediated inflammatory diseases 
(IMIDs): virtually any autoimmune condition is associated with 
particular HLA-class I or class II alleles (29–31). For most of these 
diseases, the HLA association explains more disease risk than 
any other gene locus. While IMIDs share many of the non-HLA 
loci, the associated HLA-class I and/or class II alleles are usually 
disease specific (32). This attributes the HLA alleles with a high 
degree of disease specificity and pleads for a direct causal role 
in the pathogenesis of the respective IMID. The association with 
HLA-C*06:02 in psoriasis is particularly intriguing because only 
3 of more than 12,000 different HLA-class I alleles show a strong 
disease linkage: HLA-B*27 with ankylosing spondylitis, HLA-
B*51 with Behçet’s disease, and HLA-C*06:02 with psoriasis.
Human leukocyte antigen-class I molecules are expressed by 
all nucleated cells. They present peptide antigens of usually 8–10 
amino acids to αβ T-cell receptors (TCRs) of CD8+ T cells (33). 
The antigenic peptides are derived from cytoplasmic proteins, i.e., 
proteins produced within the cells. They are processed from the 
TABLe 1 | Amino acids at anchor residues 2 and 9 of peptide antigens  
and ADAMTS-like protein 5 (ADAMTSL5) presented by psoriasis-associated 
human leukocyte antigen (HLA) molecules.
HLA molecule Residue 2 Residue 9
HLA-C*06:02 R/Y/Ka L/V/I/Y/F/M
HLA-C*07:01 R/T/N L/F/Y/M
HLA-C*07:02 R/Y/K L/Y/F/M
HLA-B*27 R L
ADAMTSL5 peptide R L
aOne letter amino acid code; font size approximately reflects the relative frequency of 
the respective amino acid observed at this position in peptides eluted from the HLA 
molecules according to Ref. (44–45).
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parent proteins by the proteasome for loading into the peptide-
binding groove of the HLA-class I molecules. The complex 
of peptide and HLA-class I molecule is transported to the cell 
membrane for recognition by CD8+ T cells (34, 35). Accordingly, 
an HLA-class I-restricted immune response must be directed 
against a particular target cell which expresses the antigenic 
protein within the cytoplasm.
Human leukocyte antigen alleles are extremely polymorphic. 
Sequence variation is concentrated in the α1 and α2 domains 
that contain the binding sites for peptide antigens and interact 
with the TCR. HLA polymorphisms result in variable peptide-
binding grooves. They contain two or three specific acceptor sites 
or pockets which bind specific amino acid side chains of peptides 
and thus define the spectrum of antigenic peptides a particular 
HLA molecule can present (35, 36). Due to the diverse acceptor 
sites, different HLA molecules select different peptide repertoires 
for presentation (37, 38), although the binding specificities may 
overlap (39, 40). Because the peptide residues in between the 
anchors may be flexibly occupied a single HLA-class I molecule 
can theoretically display between 6  ×  205–7 different decamer 
peptides (36, 41, 42).
The amino acid motifs of peptides presented by HLA-C*06:02 
and several other HLA-class I molecules have recently been char-
acterized in detail (43–45). Nonamer peptides presented by HLA-
C*06:02 show select amino acids at the anchor residues 2 and 9, 
and a potentially secondary anchor at residue 7 (Table 1). The 
dominant amino acids are arginine at residue 2, leucine, valine, 
and less preferred isoleucine and methionine at residue 9, and 
arginine at residue 7. As a particular feature, HLA-C*06:02 has very 
negatively charged pockets defining peptides with large posi tively 
charged amino acids at residue 2 (B-pocket) and 7 (E-pocket) and 
thus selects a distinct repertoire of positively charged peptides. 
The studies of Di Marco et al. (43) and Mobbs et al. (44) further 
provided an estimate of the spectrum of self-peptides presented 
by HLA-C*06:02 and other HLA-C molecules. Depending on the 
experimental approach peptide elution identified between 1,000 
and 3,000 different self-peptides from HLA-C*06:02 expressed 
in a B-cell line (43, 44). Thus, a substantial part of the cellular 
proteome should be immunolo gically visible to CD8+ T cells (44).
According to the peptide-binding pattern HLA-C*06:02 
was assigned to the same HLA supertype as other psoriasis-
associated HLA alleles including HLA-C*07:01, HLA-C*07:02, 
and HLA-B*27 (43). All of them utilize the same anchor residues 
and present peptide repertoires that may partly overlap (Table 1) 
(43–45). HLA-C*06:02 further shares the strong negative charge 
of the E-pocket with HLA-C*12:03 (44) which has several 
similar functional domains and peptide-binding pockets as HLA- 
C*06:02 (46) and constitutes another potential HLA-risk allele for 
psoriasis and psoriatic arthritis (20, 23). Thus, several psoriasis- 
associated HLA-class I molecules have overlapping peptide-
binding properties and might replace each other in conferring 
psoriasis risk. Due to the strength of association, HLA-C*06:02 
may be considered the representative HLA-risk allele within this 
spectrum and should therefore be particularly suitable for analy-
zing the role of HLA in psoriasis pathogenesis.
THe TARGeT CeLL AnD  
AUTOAnTiGenS OF An HLA-C*06:02-
ReSTRiCTeD PATHOGeniC PSORiATiC  
T CeLL ReSPOnSe
Heritability is an estimation of how much variation in a disease 
can be explained by particular genetic variants. Genetic infor-
mation then has to be combined with functional analysis to allow 
for a precise definition of the particular role of certain genes in 
disease. The actual immunological role of HLA-class I molecules 
suggests that HLA-C*06:02 may predispose to psoriasis by 
presentation of an autoantigen from a skin-specific cell popula-
tion. Identification of target cell and potential autoantigens of 
the psoriatic immune response therefore appeared as the major 
challenge for clarifying psoriasis pathogenesis.
This approach requires the TCRs of the pathogenic T-cell 
response. The paired α- and β-chains of TCRs define both HLA 
restriction and fine peptide specificity of a T cell (47). Because of 
the high diversity of the human TCR repertoire any two T cells 
expressing the same αβ-TCR heterodimer likely arose from a 
common progenitor T cell (48). In response to antigen stimula-
tion, T cells become activated and undergo clonal expansion at 
the site of antigen exposure. In the obvious absence of infections, 
expanded TCR clonotypes are commonly viewed to characterize 
those T cells relevant for the pathogenesis of IMIDs (48, 49).
Psoriasis lesions develop upon epidermal infiltration and 
activation of CD8+ T cells (50, 51). Marked oligoclonality of the 
T-cell populations within psoriatic skin lesions indicated that 
psoriatic T-cell activation is driven by locally presented antigens 
(52–56). Lesional T-cell clones were strictly associated with pso-
riatic skin lesions and reappeared in relapsing psoriasis (52, 56). 
T-cell clonality was definitely proven by single cell TCR analysis 
and particular evident for CD8+ T  cells in lesional epidermis 
(52, 54). Accordingly, the clonal TCRs likely characterized those 
CD8+ T cells which mediate psoriatic inflammation. To identify 
potential targets of the pathogenic psoriatic T-cell response we 
expressed the paired α- and β-chains of clonal CD8+ T cells from 
the psoriatic T-cell infiltrate along with human CD8 α and β 
chains in a T-hybridoma cell line that reports on TCR signaling 
through the expression of super green fluorescence protein under 
control of NFAT (Figure 1) (57, 58). Consequently, these TCR 
hybridomas carried the specificity of the pathogenic psoriatic 
FiGURe 1 | Proof of the HLA-C*06:02-restricted autoimmune response against melanocytes in psoriasis. Following separation of epidermis and dermis of lesional 
biopsies from HLA-C*06:02+ psoriasis patients CD8+ T cells (A) were isolated from epidermal cell suspensions using magnetic beads coated with CD8 antibodies. 
The arrow “A” points to a CD8+ T cells (encircled) isolated from lesional psoriatic epidermis which is rosetted by magnetic beads with a melanocyte attached. T-cell 
receptor (TCR) α and β chain mRNA of single T cells was transcribed into cDNA and sequenced by a newly developed method for single cell TCR analysis (54), 
cloned into expression plasmids and (B) expressed in a TCRα−β− mouse reporter T-hybridoma cell line stably transfected with a plasmid for super green fluorescent 
protein under control of NFAT (57–59). The TCR hybridoma cells were cocultured with various primary cell types or cell lines either positive or negative for 
HLA-C*06:02 (C). Upon TCR ligation, the hybridoma cells produce green fluorescent protein which was visualized by UV-fluorescence microscopy or FACS analysis 
(D). (E) Shows the activation of the Vα3S1/Vβ13S1-TCR hybridoma by spindle-shaped HLA-C*06:02+ primary melanocytes in a coculture experiment.
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T cells and allowed for an unbiased, i.e., hypothesis-free analysis 
of the immunologic targets of the pathogenic psoriatic immune 
response.
Using a paradigmatic Vα3S1/Vβ13S1-TCR from an epidermal 
CD8+ T-cell clone of an HLA-C*06:02-positive psoriasis patient, 
we could identify melanocytes as HLA-C*06:02-restricted target 
cells of the psoriatic immune response (Figure 1) (59). By means 
of plasmid-encoded peptide libraries, we then determined the 
amino acid pattern of HLA-C*06:02-presented peptide ligands 
of the Vα3S1/Vβ13S1-TCR. Nonamer peptides that ligated the 
Vα3S1/Vβ13S1-TCR displayed arginine at residues 2 and 7, and 
leucine at residue 9 and thus corresponded to the conserved 
amino acid pattern which is preferentially presented by HLA-
C*06:02 and other psoriasis-associated HLA-class I molecules 
(Table 1) (43–45). Screening the human proteome and the tran-
scriptome of melanocytes with this particular amino acid pattern 
identified several peptides from natural human proteins which 
ligated the Vα3S1/Vβ13S1-TCR. Only a peptide from ADAMTS-
like protein 5 (ADAMTSL5), however, was immunogenic in the 
context of the full-length parent protein and unlike the other 
peptides could be generated through proteasomal cleavage and 
NH2-terminal ERAP1 trimming. Knock-down and mutation 
experiments finally confirmed the role of ADAMTSL5 as mel-
anocyte autoantigen (59). Blood lymphocytes of more than two-
thirds of psoriasis patients but not healthy controls responded 
to ADAMTSL5 stimulation by production of the psoriasis key 
cytokines, IL-17 or IFN-γ (59). These data proved psoriasis as 
a true T-cell mediated autoimmune disease. They indicate that 
 HLA-C*06:02 predisposes to psoriasis by mediating an auto-
immune response against melanocytes through autoantigen 
presentation. The pathogenic psoriatic Vα3S1/Vβ13S1-TCR now 
represents a unique opportunity for understanding the immu-
nopathogenesis not only of psoriasis but also of mechanisms 
of autoimmunity in general, since it is still unique in medical 
research: In no other autoimmune disease a similar approach has 
yet been successful to identify target cells and autoantigens.
The unbiased analysis of a pathogenic psoriatic TCR differs 
from other hypothesis-driven approaches for the identification 
of psoriatic autoantigens. Some of them were based on sequence 
homologies between proteins from keratinocytes and S. pyogenes 
(60, 61), a major infectious psoriasis trigger (62). The pleiotropic 
multifunctional 37 amino acid molecule LL37, which is gener-
ated by extracellular cleavage of the C-terminal part of the 170 
amino acid Cathelicidin antimicrobial peptide (63) was proposed 
a potential autoantigen because LL37 peptides induced strong 
T-cell responses in psoriasis (64). Verification of the potential 
autoantigenic character for all these potential autoantigens was 
based on peptide stimulation assays. Several of the candidate pep-
tides had been chosen according to HLA-C*06:02 anchor motifs. 
The insights into TCR polyspecificity, however, would predict 
that peptides designed this way will likely induce T-cell activation 
irrespective of pathogenic relevance (42). Furthermore, some 
5Prinz HLA and Autoimmune T-Cell Responses in Psoriasis
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of the proposed LL37 peptides did not contain the appropriate 
anchor amino acid residues for binding to HLA-C*06:02 (44). 
Without confirming that an HLA-class I-presented peptide can 
be generated from the parent protein by antigen processing and 
presentation pathways within the target cell, a role as autoantigen 
for CD8+ T cells should therefore be interpreted with care.
DiSCUSSiOn
Defining the functional role of the main psoriasis risk gene, HLA-
C*06:02, allowed for re-defining the architecture of the patho-
genic psoriatic immune response. It proposes an HLA-centered 
pathogenetic model for psoriasis and other HLA-associated 
IMIDs where a particular HLA allele represents the causal risk 
gene (65). In psoriasis, HLA-C*06:02 facilitates a T-cell medi-
ated skin-specific autoimmune response. The identification of 
melanocytes as organ-specific autoimmune target cells of an 
HLA-C*06:02-restricted immune response and of ADAMTSL5 
as a melanocytic autoantigen using a pathogenic psoriatic Vα3S1/
Vβ13S1-TCR provided direct experimental evidence for the 
autoimmune nature of psoriatic inflammation, and it explained 
why psoriatic inflammation primarily affects the skin (66). The 
predisposing HLA allele appears as an essential precondition 
for a tissue- and antigen-specific autoimmune response by 
its capacity for presentation of select autoantigens. By itself, 
however, autoantigen presentation is likely not sufficient for 
causing disease onset but requires the additive effects of common 
gene variants in genes which provide the costimulatory signals 
for activation of the actual autoimmune response. The list of 
common risk gene variants in psoriasis affecting proinflamma-
tory pathways, peptide epitope trimming, IL-23 signaling and 
Th/c17 differentiation is long. It includes genes related to type I 
interferon signaling (ELMO1, TYK2, SOCS1, IFIH1/MDA5, 
RNF114, IRF4, RIG1/DDX58, IFNLR1/IL28RA, and IFNGR2), 
activation of NF-κB pathways (TNFAIP3, TNIP1, TYK2, REL, 
NFkBIA, CARD14, CARM1, UBE2L3, and FBXL19), N-terminal 
antigen trimming (ERAP1), CD8+ T-cell differentiation (ETS1, 
RUNX3, TNFRSF9, MBD2, and IRF4), and the IL-23/IL-17A axis 
(IL23R, IL12B, IL12RB, IL23A, IL23R, TYK2, STAT3, STAT5A/B, 
SOCS1, ETS1, TRAF3IP2, KLF4, and IF3). These genetic traits 
may augment responsiveness of innate immune mechanisms, 
provide a proinflammatory environment, and generate sufficient 
costi mulatory signals which may finally exceed the thresholds 
for activation, differentiation and maintenance of the pathogenic 
autoreactive T-cell response in psoriasis (65, 66). Overall, these 
insights support that proinflammatory genetic traits may promote 
autoimmunity in the presence of the appropriate HLA molecules 
which present a particular autoantigen.
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